Free Trial
NASDAQ:ALEC

Alector Q3 2023 Earnings Report

Alector logo
$1.72 +0.07 (+4.24%)
Closing price 04:00 PM Eastern
Extended Trading
$1.74 +0.02 (+0.93%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector EPS Results

Actual EPS
-$0.53
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Alector Revenue Results

Actual Revenue
$9.11 million
Expected Revenue
$9.00 million
Beat/Miss
Beat by +$110.00 thousand
YoY Revenue Growth
N/A

Alector Announcement Details

Quarter
Q3 2023
Time
N/A
Conference Call Date
Tuesday, November 7, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Alector's Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Alector Earnings Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Alector Provides Executive Leadership Update
Alector president sells shares worth $31,974
See More Alector Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email.

About Alector

Alector (NASDAQ:ALEC) is a clinical-stage biotechnology company dedicated to discovering and developing immuno-neurology therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform focuses on harnessing the innate immune system to address the underlying causes of disorders such as Alzheimer’s disease, frontotemporal dementia (FTD), and progressive multiple sclerosis (MS). By targeting key immune pathways in the brain, Alector aims to modulate microglial and macrophage function to clear toxic proteins and restore neuronal health.

The company’s pipeline features several lead programs, including AL001, an antibody designed to correct progranulin deficiencies in patients with FTD, and AL002, which targets the TREM2 receptor to enhance microglial response. Additional candidates address protein aggregation and inflammatory processes, positioning Alector at the forefront of immune-based approaches to neurodegeneration. Each program is progressing through clinical or preclinical development, with an emphasis on robust biomarker strategies to demonstrate mechanism of action and disease modification.

Founded in 2013 by Dr. Arnon Rosenthal and a team of immunologists and neuroscientists, Alector has built collaborative relationships with academic institutions and strategic partners to accelerate its research efforts. The company completed its initial public offering in 2018 and has since advanced multiple clinical trials across North America and Europe. Partnerships with leading pharmaceutical firms and research consortia have expanded access to novel targets and bolstered translational capabilities.

Headquartered in South San Francisco, with research operations in Cambridge, U.K., Alector benefits from proximity to major biotech hubs. Under the leadership of Dr. Arnon Rosenthal as President and CEO, alongside a seasoned executive team with deep experience in drug development, the company continues to build on its mission to translate cutting-edge science into therapies that address the unmet needs of patients suffering from debilitating neurodegenerative conditions.

View Alector Profile

More Earnings Resources from MarketBeat